ArticlePharmacoEconomics2020
Feasibility, Validity and Differences in Adolescent and Adult EQ-5D-Y Health State Valuation in Australia and Spain: An Application of Best-Worst Scaling.
Article in PharmacoEconomics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- How do Health State Values Differ When Respondents Consider Adults Versus Children Living in Those States? A Systematic Review.PharmacoEconomics · 2025Pooled it
- A systematic review of condition-specific preference-based measures used in young people and their valuation methods.Journal of patient-reported outcomes · 2024Pooled it
- Preference Elicitation Techniques Used in Valuing Children's Health-Related Quality-of-Life: A Systematic Review.PharmacoEconomics · 2022Pooled it
- Accounting for the Opportunity Cost of Children's Time in Economic Evaluation: Challenges and Frequently Asked Questions.Health economics · 2026Article
- EQ-5D(-Y) Valuation from Adult and Child Perspectives: Where Does the Empirical Evidence Leave Us and How Should We Proceed?PharmacoEconomics · 2026Review
- Article
- Article
- Estimating an EQ-5D-Y-3L Value Set for Brazil.PharmacoEconomics · 2024Article
- Psychometric Properties of Child Health Utility 9D (CHU9D) Proxy Version Administered to Parents and Caregivers of Children Aged 2-4 Years Compared with Pediatric Quality of Life Inventory™ (PedsQL).PharmacoEconomics · 2024Article
- Understanding Canadian stakeholders' views on measuring and valuing health for children and adolescents: a qualitative study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Scaling up a school-based intervention to increase physical activity and reduce sedentary behaviour in children: protocol for theBMJ open · 2023Article
- Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How?PharmacoEconomics · 2023Article
- Value Set for the EQ-5D-Y-3L in Hungary.PharmacoEconomics · 2022Article
- Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L.PharmacoEconomics · 2022Article
- Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among Adolescents.Applied health economics and health policy · 2022Article
- Exploring the Issues of Valuing Child and Adolescent Health States Using a Mixed Sample of Adolescents and Adults.PharmacoEconomics · 2022Article
- Adolescent valuation of CARIES-QC-U: a child-centred preference-based measure of dental caries.Health and quality of life outcomes · 2022Article
- Valuing child and adolescent health: a qualitative study on different perspectives and priorities taken by the adult general public.Health and quality of life outcomes · 2021Article
- Challenges in developing capability measures for children and young people for use in the economic evaluation of health and care interventions.Health economics · 2021Article
- Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe measurement and valuation of health-related quality of life for and by young people are increasingly important, yet research on the impact of study perspective and validity of preferences obtained from young populations remains limited.
objectiveThe objective of this study was to evaluate the feasibility and validity of collecting EQ-5D Youth version (EQ-5D-Y) preferences from adolescents, adults, and adults from a child perspective.
methodsA profile case best-worst scaling (BWS) online survey was administered to representative Australian and Spanish adult (age ≥ 18 years) and child (age 11-17 years) samples. Adults were told to either answer from their own perspective or for a hypothetical 10-year-old child. Marginal best- and worst-choice frequencies, analysis of dominant choices, self-reported difficulty completing the tasks, and time to complete tasks were used to determine the validity of responses.
resultsIn Australia, 2134 adults and 1010 adolescents completed the survey. In Spain, 2007 adults and 1000 adolescents completed it. Analysis of marginal choice frequencies and dominant choices indicated that the pattern of responses between adolescents and adults was similar. For Australian respondents, having no mobility problems was rated as best by adolescents, while adults rated having no pain and discomfort as 'best'. In Spain, both adults and adolescents rated no pain or discomfort as 'best'. Australian adolescents rated very worried, sad or unhappy as 'worst', while Spanish adolescents, Spanish adults and Australian adults rated a lot of pain and discomfort as 'worst'.
conclusionsResults suggest preferences from adolescents using direct BWS are valid. Our descriptive analysis also suggest that there are age-related and country-specific differences in elicitation values for the EQ-5D-Y.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.